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The majority of human cervical cancers are associated with the
high-risk human papillomavirus (HPV) types. In mouse models for
HPV-associated cancers, estrogen is required for the development
of cervical and vaginal cancers. The estrogen receptor  (ER) also
is required in mice for these cancers to arise. These data are
consistent with the observation in women that long-term use of
oral contraceptives or multiple pregnancies significantly increases
the risk for cervical cancer in HPV-positive women. In the present
study, we examined whether drugs that interfere with the func-
tion of ER are effective in treating and/or preventing cervical
cancer inmice.We provide evidence that a complete ER antagonist,
ICI 182,780 (ICI), as well as a selective ER modulator, raloxifene,
efficiently clear cancer and its precursor lesions in both the cervix
and the vagina. Furthermore, ICI was capable of preventing the
onset of cancers in mice bearing precursor lesions. These findings
point to the potential value of ER antagonists in controlling
gynecological disease in the lower reproductive tracts in women.
cervix  papillomavirus  SERM
H igh-risk human papillomavirus (HPV) types, particularlyHPV16, are causally associated with human malignancies,
including cervical and vaginal cancers in women (1). New
prophylactic HPV vaccines can prevent infections by a subset of
these HPVs; however, they will not eliminate preexisting HPV
infections, new infections by high-risk HPVs not targeted by the
vaccines, or cervical cancers and precancerous lesions that arise
from those HPV infections (2). Traditional therapeutic ap-
proaches (i.e., surgery, radiotherapy, and chemotherapy) are of
limited value to patients with advanced or recurrent cervical
cancer. Consequently, cervical cancer remains the second lead-
ing cause of death by cancer among women worldwide (1, 2).
New, more effective therapeutic strategies are clearly needed.
This preclinical study identifies a potent new therapeutic ap-
proach that not only effectively treats preexisting cervical and
vaginal cancers but also can prevent their onset in a mouse model
for HPV-associated cervical carcinogenesis.
The uterine cervix is highly responsive to steroidal hormones,
such as estrogen. Correspondingly, cervical cancers most com-
monly arise in the third to fifth decade (i.e., premenopausal
period) of life in women (3). Furthermore, use of oral contra-
ceptives or high parity has been shown to significantly increase
the risk for cervical cancer in HPV-infected women (4, 5). These
observations raise the possibility that steroidal hormones, such
as estrogen, might affect cancers of the cervix, much like that of
other hormonally responsive female organs (3, 6). Estrogen
replacement therapy alone, however, does not increase the risk
for cervical cancer, and tamoxifen, a well-known estrogen
receptor (ER) antagonist in breast, has no beneficial effect on
cervical cancer (7, 8). Unfortunately, neither of these studies
controlled for infections with high-risk HPVs that are prereq-
uisite for cervical cancer (1, 2). Furthermore, tamoxifen has an
ER agonistic rather than antagonistic effect in human cervix (9).
Studies have shown a protective effect on cervical cancer by
indole-3-carbinol, a compound found in cruciferous vegetables
that favorably alters the metabolism of estrogen; however, this
drug has also been shown to inhibit the genesis of other tumors
that are not believed to depend on estrogen (10–12). Thus, the
evidence for or against a role of estrogen in cervical carcino-
genesis in humans remains limited in nature and inconclusive.
To elucidate mechanisms by which HPV oncogenes promote
cervical cancer and by which cofactors contribute to cervical
carcinogenesis, we have generated transgenic mouse models that
express HPV16 E6 and/or E7 under the control of human keratin
14 promoter that drives gene expression in stratified squamous
epithelia, natural targets for HPV infection. The progressive
disease that arises in these mouse models recapitulates various
aspects of human cervical disease, including the multiple stages
of cervical carcinogenesis, the anatomical location and his-
topathological nature of the cancers, and the expression patterns
of various biomarkers (13, 14), validating the relevance of these
preclinical models to cervical disease in women. By using these
mouse models, we have demonstrated that estrogen is required
for development of cervical cancer and that ER is crucial for
the development of atypical squamous metaplasia (ASM), which
has been proposed to be the very first step of cervical carcino-
genesis preceding the development of cervical intraepithelial
neoplasia (CIN), a precancerous cervical lesion that can progress
to cervical cancer (14–19). It is still unclear, however, whether
ER-dependent as opposed to ER-independent pathway is crucial
for the progression of CIN lesions to invasive cancer and
maintenance of cervical cancer. In the current study, we dem-
onstrate that inhibition of ER is effective in both treating and
preventing cervical cancer in mice.
Results and Discussion
Selection of ER Antagonists and Treatment Regimen.Our goal was to
use ER antagonists to evaluate the role of ER in cervical
carcinogenesis. Selective ER modulators (SERMs) are com-
pounds that modulate activities of ER by competitively binding
to ER and altering recruitment of coactivators and/or corepres-
sors. Most SERMs are known to have ER agonistic, antagonistic,
or neutral effects, depending on tissue context, and thus a SERM
can have opposite effects in different tissue contexts (20). As far
as we could learn from the literature, none of the Food and Drug
Administration-approved SERMs had been tested for their
effect on the murine cervix. The selective ER down-regulator,
ICI 182,780 (ICI; also known as fulvestrant), inhibits nuclear
transport of ER and induces proteosomal degradation of ER.
Thus, in contrast to SERMs, ICI functions as an ER antagonist
in all tissues and is commonly referred to as a ‘‘complete’’ ER
antagonist (20). To determine whether ER is crucial for con-
tinued growth of cervical cancer, we decided first to investigate
the activities of the complete ER antagonist, ICI, in a preclinical
mouse model for HPV-associated cervical cancer. Specifically,
we used K14E6/K14E7 double-transgenic mice expressing the
HPV16 E6 and E7 oncogenes, which, when treated for 6 months
with exogenous estrogen (E2) at a physiological level sufficient
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to induce continuous estrus, develop cervical cancer at high
penetrance (15, 19). The progressive neoplastic disease arising in
these mice that culminates in cervical cancer is histopathologi-
cally indistinguishable from that observed in HPV16-infected
women or from that observed in K14HPV16 transgenic mice that
harbor the whole HPV16 early region, consistent with the fact
that E6 and E7 are the major oncogenes responsible for cervical
carcinogenesis (1, 19).
We have shown that K14E6/K14E7 double-transgenic mice
that are treated with exogenous estrogen for 6 months and
maintained for an additional 3 months without exogenous
estrogen have reduced tumor multiplicity and tumor size com-
pared with those treated with exogenous estrogen for 9 months
(15). The majority of mice (82%), however, still bear cancers. It
is unclear whether tumors in these mice are still dependent on
endogenous estrogen or are estrogen-independent. Therefore,
we decided to treat the double-transgenic mice with exogenous
estrogen for 6 months (the vast majority of these mice are
expected to develop cervical cancer) and then treat them with an
ER antagonist for 1 month without exogenous estrogen (Fig.
1A). This treatment regimen, if translatable to women, would be
relevant to cervical cancer patients who are not under contin-
uous hormonal stimulation, such as oral contraceptives, hor-
mone replacement therapy, or pregnancy.
Efficacy of ICI in Treating Cervical Cancer. K14E6/K14E7 double-
transgenic mice were initially divided into three groups:
E2(6m) group was treated with exogenous estrogen for 6
months and immediately killed; E2(6m)/no antagonist(1m)
group was treated with estrogen for 6 months, as described for
the E2(6m) group, but then maintained for one additional
month without further treatment; E2(6m)/ICI(1m) group was
treated for 6 months with estrogen, then treated for 1 month
with ICI (Fig. 1A).
Consistent with previous results (15, 19), all of the control
K14E6/K14E7 female mice [i.e., those treated for 6 months with
E2; the E2(6m) group] developed cervical cancer (Table 1).
Thus, at the time point that ICI was delivered to the E2(6m)/
ICI(1m) group (see Fig. 1A), all mice had cancer. In the
secondary control group [E2(6m)/no antagonist(1m)], which
Fig. 1. Therapeutic treatment with ICI or raloxifene for 1 month results in regression of cervical disease. (A) Treatment regimens for the therapeutic approach
are depicted. SeeMaterials andMethods for details. ICI and Ral stand for ICI 182,780 (fulvestrant) and raloxifene, respectively. (B) Comparison of cervical cancer
size in indicated treatment groups. Cancer size (largest cross-sectional area of each cancer) was determined as previously described (19). Mice that did not have
cancers were assigned a value of 0. Gray bar represents median value for each group. P values from two-sidedWilcoxon rank sum test are shown. (C) Shown are
high-magnification images of representative H&E-stained endocervical sections from indicated groups of mice. Arrows point to some dysplastic cells with dark,
enlargednuclei. Note that cervical dysplasias (CIN) are evident inmicenot treatedwith ICI (iand ii) or treatedwith ICI for 1week (iii) but are absent inmice treated
with ICI for a longer period (iv and v). The black line delineates the basement membrane that separates epithelium from underlying stroma. (Scale bar, 50 m.)
(D) Shown are low-magnification images of representative H&E-stained endocervical sections from indicated groups ofmice. Note that entire fields show cancer
in mice not treated with ICI (i and ii). Also note that epithelium of ICI-treated mice (iii and iv) is much thinner than that of untreated mice (v). The arrowhead
points to the small cancer remaining inmice treatedwith ICI for 2weeks (iii). (Scalebar, 100m.) (E) Transition fromcolumnar epithelium to squamous epithelium
is present only once in normal cervix (i; normal squamous metaplasia). In ASM, however, it occurs multiple times, and thus patches of squamous epithelium are
embeddedwithin columnar epithelium (ii and iii). Note that ASM is absent inmice treatedwith ICI (iv) or raloxifene (v). Arrows point to transition from columnar
epithelium to squamous epithelium. (Scale bar, 200 m.)
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was maintained for an additional month without further treat-
ment with either E2 or any antagonists, the majority of mice
(79%) retained cervical cancer, and their median cancer size
(0.10 mm2) was slightly reduced compared with that (0.16 mm2)
of the E2 group (Fig. 1B and Table 1). These small reductions
in the incidence and size of these cancers were not significantly
different (P 0.5). Cervical cancer multiplicity (2.3 1.4) in the
E2(6m)/no antagonist(1m) group was also reduced compared
with that (3.3  1.1) of the E2(6m) group, but this was not
statistically significant (P  0.09; Table 1). These modest reduc-
tions in tumor burden after removal of exogenous E2 for 1month
are consistent with prior observations that the withdrawal of E2
for a longer period (3 months) leads to a significant reduction in
tumor burden (15).
In contrast to the marginal differences in tumor incidence,
size, and multiplicity between the E2(6m) and E2(6m)/no
antagonist(1m) groups, mice treated with ICI for 1 month after
6-month E2 treatment [E2(6m)/ICI(1m) group] displayed highly
significant and much greater reductions in cervical cancer
incidence (8%; P  0.0003), median cancer size (0 mm2; P 
0.0003), and tumor multiplicity (0.2  0.5; P 0.003) compared
with the E2(6m)/no antagonist(1m) group (Fig. 1B; Table 1).
Cancer phenotypes in these mice were also significantly weaker
than those in mice treated with estrogen for 6 months and aged
for three additional months without treatment (15). These
results indicate that endogenous estrogen contributes to persis-
tence of cervical cancer.
It was also evident that in the entire epithelia of lower female
reproductive tracts, the majority of ICI-treated mice no longer
had cervical intraepithelial neoplasia (CIN) or vaginal intraepi-
thelial neoplasia (VIN), which are precancerous dysplastic le-
sions that can progress to cervical and vaginal cancers, respec-
tively (Fig. 1C). By comparison, CIN and VIN lesions were found
throughout the cervical/vaginal epithelia of the E2(6m) and
E2(6m)/no antagonist(1m) groups (Fig. 1C and Table 1). Ab-
sence of CIN andVINwas also observed in mice treated with ICI
only for 2 weeks, although these mice still carried small cancers
(Fig. 1Diii). Focal CIN/VIN lesions, however, remained in mice
treated with ICI for only 1 week, and epithelia of these mice were
thicker than those in mice treated with ICI for longer periods
(Fig. 1C, compare iii to iv and v).
It has been proposed that ASM is the earliest identifiable
precursor lesion to cervical cancer (14, 16). Whereas all mice in
the E2(6m) and E2(6m)/no antagonist(1m) groups displayed
ASM, none of the mice in the E2(6m)/ICI(1m) group had ASM
(Fig. 1E ii–iv).
Effect of ICI on Vaginal Disease in the Same Mice. We further
analyzed the data to determine whether ICI has a beneficial
effect on vaginal cancers arising in our experimental mice.
Reductions were seen in the incidence and tumor multiplicity in
the vagina of the E2(6m)/ICI(1m) group, but because the
penetrance of the disease in this tissue in the control groups
[E2(6m) and E2(6m)/no antagonist(1m)] is much less than that
in the cervix, these reductions were not statistically significant
(Table 1). We therefore compared the overall vaginal disease
states in these mice by giving arbitrary scores from 1 to 5 for the
worst-case disease state (no dysplasia, VIN 1–3, cancer) of each
animal as described inMaterials and Methods. Vaginal disease in
the E2(6m)/ICI(1m) group was significantly reduced compared
with that in the E2(6m)/no antagonist(1m) group (P  0.0008).
The E2(6m) and E2(6m)/no antagonist(1m) groups displayed
vaginal disease to a similar degree (P  0.6).
Efficacy of Raloxifene in Treating Cervical and Vaginal Diseases. Our
results described above indicate that a complete ER antagonist,
ICI, may be an effective drug for treating and/or preventing
cervical cancer in women. ICI, however, will induce menopausal
symptoms because it inhibits ER function in all tissues/cells.
Therefore, if one were to use ER antagonists to treat women
with cervical cancer, then SERMs would be a more appropriate
drug for most, and particularly premenopausal women. We
sought, therefore, to test a SERM for its efficacy in treating
cervical cancer in mice. Among the Food and Drug Adminis-
tration-approved, commercially available SERMs, we chose
raloxifene based on its ER antagonistic effect in the mouse
uterus and its activity profiles in human tissues: ER agonistic
effect in bone, antagonistic effect in breast, and neutral effect in
endometrium (6, 21). Raloxifene is approved for the treatment
of osteoporosis and the prevention of breast cancer, and it has
no major common side effects in women (6).
K14E6/K14E7 double-transgenic mice were treated with ex-
ogenous estrogen for 6 months and then with raloxifene for an
additional month [E2(6m)/Ral(1m) group; see Fig. 1A]. Histo-
logical analyses revealed that, similar to ICI, treatment of
tumor-bearing mice with the SERM raloxifene for 1 month
eradicated cancers and dysplasia in the cervix and vagina as well
as ASM (Fig. 1Ev and Table 1). Cervical cancer incidence and
cervical/vaginal disease status were highly significantly lower
than those of E2(6m)/no antagonist(1m) group (P  0.001).
So far, we demonstrated that two different ER antagonists,
ICI and raloxifene, are effective in curing both cancer and
dysplasia in the cervix and vagina in our transgenic mouse model
(Table 1). The epithelia of lower reproductive tracts from mice
treated with ICI or raloxifene for 2 weeks were thin, with only
two to three layers of cells (Fig. 1C), and uterine wet weight
(16.3  5.1 mg) was significantly reduced compared with that of
untreated mice (68.1  2.5 mg). These phenotypes are identical
to those observed inER-deficient mice and tissue recombinants
(16, 22). These data strongly support the conclusion that ICI and
raloxifene can eliminate the majority of both precancerous and
cancerous lesions in both the cervix and the vagina by inhibiting
ER. This conclusion is also supported by the absence of ASM
Table 1. Comparison of cervical/vaginal disease in E2-treated K14E6/K14E7 mice with or without therapeutic ICI/raloxifene treatment
Treatment group
Group
size, n
No disease Dysplasia only
Cancer and
dysplasia
Cancer
incidence, %
Tumor
multiplicity,
mean  SD
Cervix
(vagina)
CIN1
(VIN1)
CIN2
(VIN2)
CIN3
(VIN3)
Cervix
(vagina)
Cervix
(vagina)
Cervix
(vagina)
E2(6m) 6* 0 (0) 0 (0) 0 (1) 0 (2) 6 (3) 100 (50) 3.3  1.1 (0.5  0.5)
E2(6m)/no antagonist(1m) 14 0 (0) 0 (0) 0 (3) 3 (6) 11 (5) 79 (36) 2.3  1.4 (0.4  0.6)
E2(6m)/ICI(1m) 13 12 (12) 0 (0) 0 (0) 0 (0) 1 (1) 8 (8) 0.2  0.5 (0.1  0.3)
E2(6m)/Ral(1m) 7 7 (6) 0 (0) 0 (0) 0 (1) 0 (0) 0 (0) 0.0  0.0 (0.0  0.0)
CIN1 (VIN1) indicates low-grade dysplasia; CIN2(VIN2), midgrade dysplasia; CIN3(VIN3), high-grade dysplasia.
*Two mice were killed before the study end point (at 5.5 months of E2 treatment) because of morbidity.
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in ICI- or raloxifene-treated cervices because genetic deletion of
ER renders mice resistant to the development of ASM (16).
Some Cancers Remain After ER Antagonist Treatment.Although ICI
was extremely efficient in clearing established cancers as de-
scribed above, 2 of 13 mice in the E2(6m)/ICI(1m) group
retained tumors (Table 1). We do not know whether these
tumors were just more slowly regressing or are, in fact, ICI-
resistant tumors. We predict that the latter possibility is likely
because epithelia near the cancers remaining after ICI treatment
were as thick as those in mice not treated with ICI, whereas the
rest of epithelia in these mice were hypoplastic, identical to those
in ICI-treated, cancer-free mice (Fig. 2A; see also Fig. 1C). One
possibility is that the cancers retained in the ICI-treated mice
and/or their associated stroma are producing their own estrogen,
which leads to locally elevated estrogen concentrations sufficient
to suppress antagonistic function of ICI. In this regard, some
human cervical cancers overexpress aromatase, a rate-limiting
enzyme in estrogen biosynthesis (23). Therefore, aromatase
inhibitors may be effective in treating these potentially ICI-
resistant cervical/vaginal cancers. Although these residual can-
cers still express ER (Fig. 2B), it is also possible that these
tumors are ER-independent, as is found to be the case in a
subset of tumors arising in the human breast, another estrogen-
responsive tissue (6).
Prevention of Cervical Cancer Development by ICI.CIN and VIN are
thought to be the precursor lesions to cervical and vaginal
cancers, respectively. Because these lesions largely disap-
peared in ICI- or raloxifene-treated mice (Table 1), we
performed an additional experiment to determine whether ER
antagonists can prevent the onset of cervical/vaginal cancers.
To address this, we began treating mice with ICI after only 3
months of E2 treatment (Fig. 3A), a time period at which
CINs/VINs are present but no cancers have yet developed [Fig.
3B; Table 2, E2(3m) group]. Mice treated with ICI for 1 month
at the 3-month time point [E2(6m)/preventive ICI(1m) group]
showed neither CIN nor cervical cancer at the 6-month
endpoint (Table 2). Cervical epithelium of the E2(6m)/
preventive ICI(1m) group was almost identical to that of
age-matched untreated K14E6/K14E7 mice in estrus (Fig. 3B).
These phenotypes are significantly different from those of the
E2(6m) group that had not received ICI (P  0.002, cervical
cancer incidence; P  0.0009, cervical disease). Thus, inhibi-
tion of ER not only promotes regression of cervical cancer
but also prevents the development of this malignancy in mice.
The E2(6m)/preventive ICI(1m) group also displayed a sig-
nificantly lower degree of vaginal disease compared with the
E2(6m) group (P  0.002) (Table 2).
A relevant question we also tried to answer in this study is
whether cancers recur rapidly after ER antagonist treatment is
ceased. To answer that question, we held a subset of mice in
E2(6m)/ICI(1m) group for an additional 6 weeks after the
1-month treatment with ICI, and during this 6-week period we
put them back on exogenous estrogen treatment. At the endpoint
we observed neither cancers nor even CIN lesions. Rather, we
found the cervical epithelia to remain hypoplastic, similar to that
observed in the E2(6m)/ICI(1m) group. We interpret these data
to indicate that ICI is sustained in the mouse system for a long
time at levels high enough to inhibit ER. Such sustained ICI
Fig. 2. Cancers remainingafter therapeutic ICI treatmentareassociatedwith
nonhypoplastic epithelium. (A) (Left) Low-magnification images of the two
cancers [one cervical (Upper) and the other vaginal (Lower)] that persisted in
2 of 13mice treated with ICI for 1 month. Black and gray arrowheads point to
cancers and cancer-associated epithelia, respectively. (Scale bar, 100 m.)
(Right) High-magnification images of cervical (Upper) or vaginal (Lower)
epithelium that was immediately juxtaposed to these two cancers. Note the
nonhypoplastic (i.e., thick) epithelium akin to what is seen in female mice in
normal estrus (see Fig. 1Dv). This is in stark contrast to thehypoplastic epithelia
found elsewhere in the reproductive tracts of these same ICI-treated mice
(Insets), as well as in the other ICI-treated, cancer-free mice (see Fig. 1Cv).
White arrowheads point to dysplastic cells. Black lines delineate the basement
membrane. (Scale bar, 50 m.) (B) Cancers remaining in ICI-treated mice
express ER. Tissues were stained for ER (red) and K14 (green), an epithelial
cell marker. Arrowheads and arrows point to cancers and cancer-associated
epithelia, respectively. (Scale bar, 50 m.)
Fig. 3. One-month ICI treatment prevents the onset of cervical cancer. (A)
Treatment regimens for the preventive approach are depicted. SeeMaterials
and Methods for details. (B) Shown are high-magnification images of repre-
sentative H&E-stained endocervical sections from indicated groups of mice.
Unlike epithelia of mice in the E2(6m) or E2(3m) group, those in the E2(6m)/
preventive ICI(1m) group are indistinguishable from normal epithelia of un-
treated mice in estrus. Black lines delineate the basement membrane. (Scale
bar, 25 m.)
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activity prevents us from evaluating whether recurrence of
disease is an issue. Thus, we are currently investigating other
SERMs, including raloxifene, to identify an ER antagonist
suitable for experiments to address this question.
The findings from our preclinical studies are consistent with
the hypothesis that ER is necessary for the progression and
maintenance of cervical cancer in mice. Therefore, we predict
that other drugs that inhibit the estrogen-ER pathway in the
cervix should have similar therapeutic and preventive effects
on cervical cancer. We have demonstrated that ER is indeed
necessary for the development of ASM, which is thought to be
a precursor for cervical cancer and to originate from a specific
cell type called reserve cells in the cervical transformation
zone (14, 16). Taken together, we propose a model in which
reserve cells are the precursor cell type for cervical carcino-
genesis, and after HPV16 infection they slowly progress to
ASM, CIN, and then cancer in the presence of estrogen and
ER (Fig. 4) These two factors are also required for the
persistence of cervical cancer. ER antagonists can cause
efficient regression of cancer, dysplasia, and ASM and prevent
malignant progression. Requirement for HPV oncogenes in all
steps of cervical carcinogenesis has been well-demonstrated in
both cervical cancer-derived cell lines and transgenic mouse
models (24–26). Although our transgenic mouse model for
HPV-associated cervical cancer recapitulates most aspects of
human cervical cancer (13, 14, 19), it is obvious that further
study is needed to determine whether this proposed model is
relevant to human cervical cancer. If it proves relevant, then
it would have clear implications in the prevention and control
of malignant cervical and vaginal disease in women, and it may
provide alternatives to currently available modalities for treat-
ing cervical cancer and precursor lesions. It would also raise
some concerns that the use of tamoxifen, a SERM with ER
agonist activities in the human female reproductive tract, or
estrogen (hormone) replacement therapy could lead to in-
creases in cervical neoplasia in HPV-infected women.
Materials and Methods
Mice. K14E7 and K14E6 transgenic mice were designed to express HPV16 E7
and E6, respectively, in stratified squamous epithelia, natural HPV infection
sites in humans (27, 28). Female progenies were genotyped by PCR, and a
slow-releasing 17-estradiol (E2) tablet (0.05mg, 60days; Innovative Research
of America) was inserted s.c. under the dorsal skin every 2 months beginning
at 4–6weeks of age. After 6-month treatmentwith E2, onegroupofmicewas
killed immediately to evaluate cancer phenotypes [E2(6m) group], another
groupwasmaintained for anothermonthwithout further treatment [E2(6m)/
no antagonist(1m) group], and the third group was treated for a month with
ICI [E2(6m)/ICI(1m) group] or raloxifene [E2(6m)/Ral(1m) group]. For the pre-
vention study, mice were treated with E2 for 3 months and were either killed
[E2(3m) group] or treated with ICI and E2 for a month and then E2 for two
more months [E2(6m)/preventive ICI(1m) group]. Female reproductive tracts
were harvested at each end point, fixed in paraformaldehyde, and embedded
in paraffin. Every tenth 5-m section was stained with H&E and histopatho-
logically scored to identify the worst grade of cervical/vaginal disease present
and size of cancers in each animal, as previously described (19). Mice were
housed inMcArdle LaboratoryAnimal CareUnit of theUniversity ofWisconsin
Medical School, approved by the Association for Assessment of Laboratory
Animal Care. All procedures were carried out according to an animal protocol
approved by the University of Wisconsin Medical School Institutional Animal
Care and Use Committee.
Drug Treatment. Faslodex (50 mg/mL; human formulation for intramuscular
injection of ICI; Astra Zeneca) was purchased from the University ofWisconsin
Hospital Pharmacy. Mice were s.c. injectedwith 0.15mL (equivalent to 7.5 mg
of ICI) of Faslodex twice a week for a month (total of nine injections). EVISTA
tablets (Eli Lilly), which are a human formulation of raloxifene (60 mg per
tablet) were also purchased from the University of Wisconsin Hospital Phar-
macy. Tablets were resuspended in PBS at a final concentration of 10 mg/mL.
Mice were injected i.p. with 1.5 mg of raloxifene for a month, 5 days a week.
These treatments increased neither morbidity nor mortality.
Immunohistochemistry. Paraffin-embedded female reproductive tracts were
stained with anti-ER and anti-keratin 14 antibodies as previously de-
scribed (16).
Statistical Analyses. Two-sided Fisher’s exact test was used for statistical
analyses of cancer incidence and two-sided Wilcoxon rank sum test for those
of disease state, cancer size, and tumor multiplicity, respectively. Two-sided
analyses were carried out with MSTAT software version 12.0.0 (www.mcar-
dle.wisc.edu/mstat). For assessing overall disease states, arbitrary scores were
given to each lesionas follows: nodysplasia1; CIN1 (VIN1)2; CIN2 (VIN2)
3; CIN3 (VIN3)  4; and cancer  5; the datasets were compared by using the
Wilcoxon rank sum test.
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Table 2. Comparison of cervical/vaginal disease in E2-treated K14E6/K14E7 mice with or without preventive ICI treatment
No disease Dysplasia only
Cancer and
dysplasia
Cancer
incidence, %
Treatment group
Group
size, n
Cervix
(vagina)
CIN1
(VIN1)
CIN2
(VIN2)
CIN3
(VIN3)
Cervix
(vagina)
Cervix
(vagina)
E2(3m) 6 0 (2) 1 (2) 3 (2) 2 (0) 0 (0) 0 (0)
E2(6m)/preventive ICI(1m) 6 6 (6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
E2(6m)* 6 0 (0) 0 (0) 0 (1) 0 (2) 6 (3) 100 (50)
*Same group as described in Table 1.
Fig. 4. A model for cervical carcinogenesis. See the text for details.
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